LKLarysa Kuts

Larysa Kuts

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Larysa Kuts has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nephrotic syndrome: Management of dyslipidemia, pathophysiological insights, and therapeutic perspectives

    by Mariia Cherska, Olena Pavlenko, Vira Zlatkina, Larysa Kuts, Karina Taraniuk, Oleksii Demikhov, Tatyana Storozhenko, Daniela Koleva-Tyutyundzhieva, Krystyna Kukharchuk, Ahmed El Gohary, et al.

    Dyslipidemia is a characteristic feature of nephrotic syndrome (NS), which significantly increases the risk of cardiovascular complications and progression of chronic kidney disease. This review analyzes current understanding of the complex pathophysiological mechanisms of lipid metabolism disorders in NS. Particular attention is paid to the impact of proteinuria on the synthesis of lipoproteins by the liver and impaired clearance. The article systematizes current therapeutic strategies. Therapeutic prospects aimed at correcting the lipid profile as a means of nephroprotection are considered. The review emphasizes the need for a personalized approach to the management of dyslipidemia, taking into account the etiology of NS and the functional state of the kidneys.

  • Open Access

    Diagnostic and therapeutic potential of interleukin-37 in kidney diseases: A mini-review

    by Nadiia Demikhova, Larysa Kuts, Svitlana Bokova, Eda Merisalu, Olga Vlasenko

    Interleukin-37 (IL-37) is a newly discovered anti-inflammatory cytokine from the IL-1 family that plays a key role in regulating both innate and adaptive immune responses. It is secreted in healthy tissues, reflecting a homeostatic function. Intracellularly, IL-37 suppresses diverse inflammatory signals in various cells, including dendritic cells, macrophages, epithelial cells, and endothelial cells. Although it has been studied in many conditions, such as autoimmune disorders, cancer, and cardiovascular disease, its specific role in kidney diseases remains relatively understudied. In this mini-review, we summarize current evidence on the biology of IL-37, with a focus on its relevance to kidney disease. We explore its molecular structure, patterns of expression, and the immunomodulatory mechanisms that may influence kidney diseases, including acute kidney injury, diabetic nephropathy, and autosomal dominant polycystic kidney disease. We also discuss the challenges of translating IL-37-based therapies into clinical practice and highlight key areas for future research aimed at unlocking its potential in the treatment of kidney diseases.